NCT06706050View on ClinicalTrials.gov

Clinical Therapeutic Potential of Novel Microbiome LP-51 on Xerosis Individual Based on Xerosis-microbiome Index

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

May 8, 2023

Primary Completion Date

June 16, 2023

Study Completion Date

November 6, 2023

Conditions
Xerosis
Interventions
BIOLOGICAL

Microbiome Therapeutic LP-51

Microbiome therapeutics LP-51 was applied on the individuals suffering from xerosis

OTHER

placebo cream (M23004-03)

placebo cream (M23004-03) was applied on the participants

Trial Locations (1)

31538

Soonchunhyang University Probiotics Microbiome Convergence Center (PMC) Skin Clinical Evaluation Research Institute, Asan

All Listed Sponsors
collaborator

National Research Foundation of Korea

OTHER

collaborator

Ministry of Trade, Industry and Energy

UNKNOWN

collaborator

Soon Chun Hyang University

OTHER

lead

Ho-Yeon Song

OTHER

NCT06706050 - Clinical Therapeutic Potential of Novel Microbiome LP-51 on Xerosis Individual Based on Xerosis-microbiome Index | Biotech Hunter | Biotech Hunter